New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
08:03 EDTIG, IPXLIGI Laboratories completes seventh ANDA filing under joint agreement with Impax
IGI Laboratories (IG) announced it has submitted its seventh abbreviated new drug application in 2014 to the FDA. The seventh ANDA submission was in connection with an existing development, supply and marketing agreement with Impax Laboratories (IPXL). The agreement designates IGI Laboratories as the developer, manufacturer, and owner of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by Global Pharmaceuticals, Impax's generics division. In accordance with the agreement, Impax is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA.
News For IG;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
08:16 EDTIGIGI Laboratories downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 23, 2014
16:30 EDTIGIGI Laboratories sees 2014 revenue $31.5M-$33M, consensus $29.17M
Sees 2014 net income $2M-$3M.
16:29 EDTIGIGI Laboratories reports Q3 EPS 0c, consensus (1c)
Subscribe for More Information
October 22, 2014
10:09 EDTIPXLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:58 EDTIPXLImpax initiated with an Outperform at JMP Securities
Subscribe for More Information
October 10, 2014
16:40 EDTIGJanus Capital Management reports 10.1% passive stake in IGI Laboratories
10:01 EDTIPXLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:35 EDTIPXLImpax upgraded to Buy from Hold at WallachBeth
Subscribe for More Information
06:58 EDTIPXLImpax upgraded to Buy from Hold at Needham
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use